Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]Lorlatinib in healthy male volunteers
NCT02564562Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Nov 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Mass Balance at 14 days, Metabolic profiling / metabolite identification at 14 days and 12 more. Started Oct 2015; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02564562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564562.